ANGIOEDEMA: ETIOLOGY, PATHOPHYSIOLOGY, CURRENT AND EMERGING THERAPIES

作者：Lewis Lawrence M^*

来源：Journal of Emergency Medicine, 2013, 45(5): 789-796.

DOI：10.1016/j.jemermed.2013.03.045

• angioedema
• kallikrein-kinin system
• ecallantide
• icatibant
• angiotensin-converting enzyme inhibitor induced angioedema

Background: Angioedema (AE) is characterized by nonpitting edema of the dermis and subcutaneous layers. The most common sites of involvement are the tongue, lips, face, and throat; however, swelling can also occur in the extremities, genitalia, and viscera. Life-threatening airway swelling can also occur. AE may be allergic or nonallergic. The overall lifetime incidence of AE is reported to be as high as 15%. Objective: This article summarizes the etiology, pathophysiology, and current treatment of several forms of nonallergic AE (including hereditary, acquired, and idiopathic AE) and focuses on angiotensin-converting enzyme inhibitor-induced angioedema (ACEi-AE), which is responsible for 30% - 40% of all AE seen in United States emergency departments. Discussion: Although the triggers, which are primary biologic mechanisms, and treatments for ACEi-AE may differ from those of the hereditary and acquired forms of AE, the clinical effects of ACEi-AE are mediated through a shared pathway, the kallikrein-kinin system. Thus, although current therapeutic options for ACEi-AE are limited, recent advances in the treatment of hereditary AE (HAE) appear promising for improving the outcomes of patients with ACEi-AE. Conclusions: New HAE medications that correct imbalances in the kallikrein-kinin system may prove safe and efficacious in the treatment of ACEi-AE.

• 出版日期2013-11